1 EXECUTIVE SUMMARY

2 METHODOLOGY

3 TRENDS AND DRIVERS

• 3.1 Drugs for Non-small Cell Lung Cancer Market Size and Trends
• 3.2 Opportunities in Drugs for Non-small Cell Lung Cancer
• 3.3 Market Inhibitors

4 MARKET DYNAMICS

• 4.1 Drugs for Non-small Cell Lung Cancer Industry Chain
• 4.2 Drugs for Non-small Cell Lung Cancer Cost Analysis
• 4.3 Drugs for Non-small Cell Lung Cancer Pricing Strategy
• 4.4 Distribution Structure
• 4.5 Enter Strategy

5 MARKET AND TECHNICAL CHALLENGES

• 5.1 Commercialization Stage
• 5.2 Economic Impact
• 5.3 Competitive landscape Overview
• 5.4 Regulatory/Government policy

6 PORTER’S FIVE FORCE ANALYSIS

• 6.1 Threat of New Entrants
• 6.2 Bargaining Power of Suppliers
• 6.3 Bargaining Power of Buyers
• 6.4 Threat of Substitute
• 6.5 Segment Rivalry

7 Value Chain Analysis

• 7.1 Upstream Overview
• 7.2 Companies Distribution
• 7.3 Brand and Processing
• 7.4 Distribution Channel

8 Drugs for Non-small Cell Lung Cancer MARKET, BY TYPE

• 8.1 Overview
• 8.2 Market Size & Analysis, By Type
  • 8.2.1 Radiofrequency Ablation (RFA)
  • 8.2.2 Radiation Therapy
  • 8.2.3 Chemotherapy
  • 8.2.4 Targeted Therapies
  • 8.2.5 Immunotherapy

9 Global MARKET, BY REGIONS

• 9.1 Global Market Size and Share by Regions
• 9.2 North America Market
  • 9.2.1 US
  • 9.2.1 Canada
  • 9.2.1 Mexico
• 9.3 Europe Market
  • 9.3.1 UK
  • 9.3.2 Sweden
  • 9.3.3 Germany
  • 9.3.4 Spain
  • 9.3.5 Russia
  • 9.3.6 France
  • 9.3.7 Rest of Europe
• 9.4 Asia & Pacific Market
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Korea
  • 9.4.5 Australia
  • 9.4.6 Southeast Asia
  • 9.4.7 Rest of Asia & Pacific
• 9.5 LAMEA Market
  • 9.5.1 Latin America
  • 9.5.2 Middle East
  • 9.5.3 Africa

10 Top Company

• 10.1 Bristol-Myers Squibb
  • 10.1.1 Business Overview
  • 10.1.2 Recent Development
• 10.2 GlaxoSmithKline
• 10.3 Menarini
• 10.4 Sanofi
• 10.5 Ziopharm Oncology
• 10.6 Alchemia
• 10.7 Amgen
• 10.8 Apotex
• 10.9 BioMarin Pharmaceutical
• 10.10 CellAct Pharma
• 10.11 Cerulean Pharma
• 10.12 Cipla
• 10.13 Cornerstone Pharmaceuticals
• 10.14 Curis
• 10.15 CytRx
• 10.16 Eli Lilly
• 10.17 Exelixis
• 10.18 Fresenius Kabi
• 10.19 Genentech
• 10.20 Hikma Pharmaceuticals
• 10.21 Hospira
• 10.22 Intas Pharmaceuticals
• 10.23 Karyopharm Therapeutics
• 10.24 Kyowa Hakko Kirin
• 10.25 Ligand Pharmaceuticals

11 Market Forecast

• 11.1 Global Market Forecast
• 11.3 Market Forecast by Type
• 11.3 Market Forecast by Region

12 Conclusion

Summary

The Drugs for Non-small Cell Lung Cancer report provides an independent information about the Drugs for Non-small Cell Lung Cancer industry supported by extensive research on factors such as industry segments
size & trends, inhibitors, dynamics, drivers, opportunities & challenges, environment & policy, cost overview, porter’s five force analysis, and key companies profiles including business overview and recent development.
The report would be based on industry data clearly referenced from authentic and reliable information sources such as statistics, industry associations, website of ministry and companies etc, market research reports, magazines, trade journals, annual reports, presentations, telephone interview etc.
The report includes regions as follows:
North America
US
Canada
Mexico
Europe
UK
Sweden
Germany
Spain
Russia
France
Rest of Europe
Asia & Pacific
China
Japan
India
Korea
Australia
Southeast Asia
Rest of Asia & Pacific
LAMEA
Latin America
Middle East
Africa
The report will be delivered with 2-3 working days. Custom contents with more cost can be added if the customer wants deeper any facet of the report with specific requirements.